Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Nov;107 Suppl 1(0 1):5-27.
doi: 10.1111/j.1360-0443.2012.04035.x.

Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review

Hendrée E Jones  1 , Sarah H Heil, Andjela Baewert, Amelia M Arria, Karol Kaltenbach, Peter R Martin, Mara G Coyle, Peter Selby, Susan M Stine, Gabriele Fischer
Affiliations
Review

Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review

Hendrée E Jones et al. Addiction. 2012 Nov.

Abstract

Aims: This paper reviews the published literature regarding outcomes following maternal treatment with buprenorphine in five areas: maternal efficacy, fetal effects, neonatal effects, effects on breast milk and longer-term developmental effects.

Methods: Within each outcome area, findings are summarized first for the three randomized clinical trials and then for the 44 non-randomized studies (i.e. prospective studies, case reports and series and retrospective chart reviews), only 28 of which involve independent samples.

Results: Results indicate that maternal treatment with buprenorphine has comparable efficacy to methadone, although difficulties may exist with current buprenorphine induction methods. The available fetal data suggest buprenorphine results in less physiological suppression of fetal heart rate and movements than methadone. Regarding neonatal effects, perhaps the single definitive conclusion is that prenatal buprenorphine treatment results in a clinically significant less severe neonatal abstinence syndrome (NAS) than treatment with methadone. The limited research suggests that, like methadone, buprenorphine is compatible with breastfeeding. Data available thus far suggest that there are no deleterious effects of in utero buprenorphine exposure on infant development.

Conclusions: While buprenorphine produces a less severe neonatal abstinence syndrome than methadone, both methadone and buprenorphine are important parts of a complete comprehensive treatment approach for opioid-dependent pregnant women.

Trial registration: ClinicalTrials.gov NCT00271219.

PubMed Disclaimer

References

    1. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25(1):139–151. - PubMed
    1. Jones HE, Tuten M, Keyser-Marcus L, Svikis D. In: Specialty treatment for women, in Methadone treatment for opioid dependence. Strain EC, Stitzer ML, editors. Johns Hopkins University Press; Baltimore: 2006. pp. 455–484.
    1. Unger A, Jung E, Winklbaur B, Fischer G. Gender issues in the pharmacotherapy of opioid-addicted women: buprenorphine. J Addict Dis. 2010;29(2):217–30. - PMC - PubMed
    1. Winklbaur B, Kopf N, Ebner N, Jung E, Thau K, Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction. 2008;103(9):1429–40. - PubMed
    1. Winklbaur B, Jung E, Fischer G. Opioid dependence and pregnancy. Curr Opin Psychiatry. 2008;21(3):255–9. - PubMed

Publication types

MeSH terms

Associated data